Zhenyu Xu Sells 4,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $7.52, for a total transaction of $30,080.00. Following the transaction, the insider owned 586,887 shares in the company, valued at approximately $4,413,390.24. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Price Performance

SOPH opened at $7.50 on Friday. The company has a fifty day moving average price of $5.89 and a two-hundred day moving average price of $5.23. The firm has a market capitalization of $629.17 million, a PE ratio of -6.52 and a beta of 0.96. SOPHiA GENETICS SA has a 52 week low of $3.10 and a 52 week high of $7.88. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analysts Set New Price Targets

SOPH has been the topic of several analyst reports. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, BTIG Research upped their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the first quarter valued at approximately $2,157,000. Finally, Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.